In the RESTORE-RA trial, structured tapering of biologic or targeted synthetic DMARDs was noninferior to standard dosing for maintaining low disease activity at 24 weeks.
2
Low disease activity was maintained by 88.2% of patients assigned to tapering and 89.6% assigned to continued treatment in the per-protocol analysis.
3
Some secondary disease activity measures favored continued treatment, although patient-reported disease activity and quality-of-life measures did not differ significantly.
4
Among 23 tapering-group patients who lost low disease activity by week 12, 17 regained it by week 24 after treatment reescalation.
5
Exploratory analyses found lower low-disease-activity maintenance with tapered JAK inhibitors than with continued JAK inhibitors, but were not powered to establish drug-class noninferiority.
